Researchers examined clinical and inflammatory outcomes in 113 patients with severe asthma who received biologic therapy. The study looked at how baseline airway inflammation patterns, such as eosinophilic or neutrophilic patterns, related to lung function and other health markers. Most neutrophilic patients in the group had elevated type 2 biomarkers, which is an interesting finding given their specific inflammation type.
During the follow-up period of 6 and 12 months, all patients showed a significant reduction in their ability to produce sputum. In terms of lung health, forced vital capacity was lower in neutrophilic patients compared to those with other patterns. Additionally, neutrophilic patients had higher frequencies of obstructive sleep apnea than those with eosinophilic patterns.
The study also noted that neutrophilic patients had lower rates of chronic rhinosinusitis with nasal polyps compared to eosinophilic subjects. No safety concerns or adverse events were reported for the patients in this group. Readers should understand that this was a retrospective observational study, meaning it can only show links between factors, not prove that one causes the other. The findings have low certainty and may not apply to all patients with severe asthma.
